A Cleveland Clinic-led analysis of real-world treatment patterns for high-risk myelodysplastic syndromes (MDS) has revealed significant underuse of guideline-recommended, life-extending therapies, particularly among women and non-white patients. The findings, published in the journal Blood Neoplasia , showed that despite being the standard of care for high-risk MDS, hypomethylating agents (HMAs) are administered to only a fraction of patients eligible to receive them, and those who do start therapy often do not complete the recommended duration.

“The disparities we found based on gender, race, and ethnicity were really striking,” said the lead author, Sudipto Mukherjee, MD, PhD, a hematologist and oncologist at Cleveland Clinic. “Given the absence of newly approved therapies over

See Full Page